Idiopathic Short Stature is a condition which leads to an impaired growth. Health care organizations define this condition as, height deviated by more than 2 standard deviations below the average height of a given sex, age and population. More than 80% of the children diagnosed with short stature are categorized as Idiopathic Short Stature. In general, there is no identifiable disorder of growth hormone (GH)/ insulin-like growth factor (IGF) and no other endocrine disorder, but in the rare case, it might be.
Idiopathic Short Stature is categorized into Familial Short Stature (FSS) - when the child remains in the range of target height but have short stature compared to reference population and Non-Familial Short Stature (NFSS) - a child is short statured when compared with both reference population and the target height.
Factors driving global demand for Idiopathic Short Stature are increasing awareness amongst people and increasing number of growth hormone options available in the market.
This report provides information on Idiopathic Short Stature market size for the year 2014-2016, and forecast of the same for year 2021. It also focuses on market drivers, challenges, restraints, market dynamics, growth indicators, competitive landscape, potential growth opportunities and other key aspects with respect to Idiopathic Short Stature treatment market.
United States and Europe remain the potential markets for Idiopathic Short Stature accounting for more than four million children. Availability of insurance aid in developed markets increases the penetration of the biologics/biosimilar drugs used in the treatment of Idiopathic Short Stature. The market is dominated by few major players, which indeed has become a major challenge for the new entrants.
This report identifies global Idiopathic Short Stature market on the basis of treatment type and regional market as follows:
- Idiopathic Short Stature treatment market is segmented based on available treatment options. Although various treatment options are in the market majority of these are not approved for growth acceleration and hence they are considered under off label use. Recombinant growth hormone therapy, Insulin like Growth Factor -1 (IGF-1) therapy, Aromatase inhibitors and low-dose androgen therapy (with injectable testosterone and low dose androgen) are the available treatment options.
- This report is further segmented based on potential markets for Idiopathic Short Stature. A detailed analysis by region – North America, Europe, Asia Pacific (APAC) and Rest of the World (RoW), has been provided in this report.
This report looks into all the major companies operating in the Idiopathic Short Stature treatment. Some of the major companies’ profiles are as follows:
- Eli Lilly
- Novo Nordisk
- Merck KGaA